Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Urology

Journal Scan / Research · April 22, 2022

Incidence of Testicular Cancer Among Transgender Women Undergoing Gender-Affirming Hormonal Treatment

BJU International


Additional Info

Disclosure statements are available on the authors' profiles:

BJU International
Incidence of testicular cancer in trans women using gender-affirming hormonal treatment: a nationwide cohort study
BJU Int 2022 Apr 01;129(4)491-497, I de Nie, CM Wiepjes, CJM de Blok, RJA van Moorselaar, GLS Pigot, TM van der Sluis, E Barbé, P van der Voorn, NM van Mello, J Huirne, M den Heijer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading